Clinical trials: Lipodystrophy Acquired, open to volunteers
Partial Lipodystrophy
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
- Trial name
- NCT06484868
- Testing
- Metreleptin
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Amryt Pharma
Generalized Lipodystrophy
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD).
- Trial name
- LAGO (NCT07220785)
- Testing
- Mibavademab
- Where
- 9 sites in United States, Brazil and 1 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Lipodystrophy Acquired, Lipodystrophy Congenital
Registry for Patients With Lipodystrophy
Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the persons affected by it calls for the monitoring of the progression over long periods of time.
- Trial name
- ECLip Registry (NCT03553420)
- Where
- 28 sites in Austria, France and 14 more
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Generalised Lipodystrophy, Partial Lipodystrophy
MEASuRE: Metreleptin Effectiveness And Safety Registry
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
- Trial name
- MEASuRE (NCT02325674)
- Testing
- Metreleptin
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Lipodystrophy (Genetic or Acquired, Non HIV)
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes
Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States.
- Trial name
- NCT03087253
- Where
- 4 sites in United States, Brazil and 1 more
- Volunteers
- 500 people
- Sponsor
- University of Michigan